Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma-Reference-Cited by-同舟云学术

Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma

Published:2021-07-24 Issue: Volume: Page:
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Ebert Lisa M.¹,Vandyke Kate²³,Johan M. Zahied¹,DeNichilo Mark¹,Tan Lih Y.¹,Myo Min Kay K.¹,Weimann Benjamin M.¹⁴,Ebert Brenton W.¹,Pitson Stuart M.¹²,Zannettino Andrew C. W.¹²³,Wallington‐Beddoe Craig T.¹⁴⁵,Bonder Claudine S.¹²^ORCID

Affiliation:

1. Centre for Cancer Biology SA Pathology and University of South Australia Adelaide SA Australia

2. Adelaide Medical School Faculty of Health and Medical Sciences The University of Adelaide Adelaide SA Australia

3. Myeloma Research Laboratory Precision Medicine Theme South Australian Health and Medical Research Institute Adelaide SA Australia

4. College of Medicine and Public Health Flinders University Bedford Park SA Australia

5. Flinders Medical Centre Bedford Park SA Australia

Funder

Cancer Australia

National Health and Medical Research Council

Cancer Council South Australia

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.13055

Reference66 articles.

1. Multiple myeloma

2. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy

3. Interpretation of cytogenetic results in multiple myeloma for clinical practice

4. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies

5. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis;Nature Communications;2024-07-09

2. Serine/threonine‐protein kinase D2‐mediated phosphorylation of DSG2 threonine 730 promotes esophageal squamous cell carcinoma progression;The Journal of Pathology;2024-02-27

3. Desmoglein-2 as a cancer modulator: friend or foe?;Frontiers in Oncology;2023-12-22

4. Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies;International Journal of Molecular Sciences;2023-04-21

5. Downregulation of desmoglein 2 promotes EMT progression in gallbladder cancer;HISTOL HISTOPATHOL;2023